Zhi Tong Cai Jing·2025-11-14 15:50Core Viewpoint - Mangoceuticals (MGRX.US) experienced significant stock volatility following the retraction of a partnership announcement with Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) [1] Group 1: Company Developments - On Thursday, Mangoceuticals claimed to have established a partnership with Eli Lilly and Novo Nordisk to provide GLP-1 weight loss medications through its MangoRx Direct and PeachesRx Direct programs [1] - The following day, both Eli Lilly and Novo Nordisk publicly denied any existing partnership with Mangoceuticals, leading to a sharp decline in the company's stock price [1] Group 2: Stock Performance - Prior to the market opening, Mangoceuticals' stock fell approximately 13%, but later recovered slightly to close up 2.94% at $1.225 [1]